PAUL device implantation in paediatric glaucoma patients with LTBP2 mutation: Case reports

Aspasia Diafa,Anna Mourgela,Margarita Papadopoulou,Spyros Atzamoglou,Aspasia Adamopoulou,Rafaela Smarlamaki,Christina Kappou,Nefeli Ioanna Paizi,Athanasios Zisimopoulos,Chrysa Terzidou,Agathi Kouri

DOI: https://doi.org/10.1111/aos.16219

2024-01-01

Acta Ophthalmologica

Abstract:Purpose: Latent‐transforming growth factor beta‐binding protein 2 (LTBP2) is a fibrillin‐related extracellular matrix protein. The protein is expressed in the ciliary body, and mutations in its gene lead to primary paediatric glaucoma due to anterior segment dysgenesis. These mutations in the Greek area appear almost exclusively in Roma families. In this work, we present the surgical treatment of two patients with PAUL® device implantation, and their preoperative and postoperative course. Methods: Case Reports. Results: Case 1: A 2‐month‐old female patient, the fifth child of a Roma family with an older sister with paediatric glaucoma, presented to the Ophthalmology clinic of our hospital with microspherophakia and megalocornea, a phenotype compatible with a mutation of the LTBP2 gene. She underwent a phakectomy for lens dislocation in both eyes. At the age of 2.5 years, she was diagnosed with hypertony and started topical treatment. After two years of treatment escalation and unsuccessful management of intraocular pressure, at the age of 4.5 years it was decided to implant a PAUL® glaucoma implant in her left eye. Case 2: An 8‐month‐old male patient, child of a Roma family, similarly presented with microspherophakia and megalocornea as well as hypertony. In addition to topical treatment, he underwent peripheral iridectomies and phakectomies in both eyes. After years of treatment escalation and unsuccessful management of intraocular pressure, at the age of 6.5 years it was decided to implant a PAUL® glaucoma implant in his left eye. We describe the surgical procedures as well as their postoperative course. Conclusions: Regular monitoring of intraocular pressure is recommended in children with megalocornea, microspherophakia and/or ectopia lentis. Genetic testing of the LTBP2 gene is recommended in these patients. It is important to raise awareness in the ophthalmological community regarding the recognition of this phenotype in children of Roma families. The PAUL® device is one of the options for treating drug‐resistant paediatric glaucoma.

ophthalmology